Keywords
bismuth, digestive tract, inflammatory diseases of the intestines.
How to Cite
Zhuravlyova, L., & Shekhovtsova, Y. (2019). The possibilities of bismuth preparations usage in gastroenterology practice: new views on application aspects. The Practitioner, (4), 29-36. Retrieved from https://plr.com.ua/index.php/journal/article/view/497
Abstract
The analysis of efficiency of bismuth substance in the conditions of the digestive tract pathology has been made in the review. The antidiarrheal activity of this combination as well as its antiedematous and antiemetic properties have been determined. The adsorbing properties of the substance on administration of endotoxins of causative agents of bacterial intestinal infections and exotoxin of cholera vibrion have been considered and also its influence on the reproduction of rotaviruses and the course of noninfectious diarrheas. Besides, the gastroprotective activity of bismuth subsalicylate on the influence of gastric factors of aggression has been shown which was complemented by its expressed antisecretory and anti-inflammatory activity against the background of inflammatory diseases of the intestines.
References
1. Yang N., Sun H. Biological chemistry of antimony and bismuth / Biological chemistry of arsenic, antimony and bismuth / H. Sun (Ed.). — Singapore: John
Wiley & Sons Ltd., 2011. — 400 р.
2. Li W., Jin L., Zhu N. et al. Structure of colloidal bismuth subcitrate (CBS) in dilute HCl: unique assembly of bismuth citrate dinuclear units ([Bi(cit)2Bi]2-) // J. Am. Chem. Soc. — 2003. — Vol. 125, № 4. — P. 2408-12409.
3. Andrews P.C., Deacon G.B., Forsyth C.M. et al. Towards a structural understanding of the anti-ulcer and anti-gastritis drug bismuth subsalicylate // Angew Chem. Int. Ed. Engl. — 2006. — Vol. 45, № 34. — P. 5638-5642.
4. Mendis A.H.W., Marshall B.J. Helicobacter pylori and bismuth / Biological chemistry of arsenic, antimony and bismuth / H. Sun (Ed.). — Singapore: John Wiley & Sons Ltd., 2011. — 400 р.
5. Morgenstern A., Bruchertseifer F., Apostolidis C. Bismuth‑213 and Actinium‑225 — generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes // Current Radiopharmaceuticals. — 2012. — Vol. 5, № 3. — P. 221-227.
6. Lee S.P. A potential mechanism of action of colloidal bismuth subcitrate; diffusion barrier to hydrochloric acid // Scand. J. Gastroenterol. — 1982. — Vol. 17, suppl. 80. — P. 17-21.
7. Turner N.C., Martin G.P., Marriott C. The influence of native porcine gastric mucus gel on hydrogen ion diffusion: the effect of potentially ulcerogenic agents //
J. Pharm. Pharmacol. — 1985. — Vol. 37, № 11. — P. 776-780.
8. Tasman-Jones C., Maher C., Thomsen L. et al. Mucosal defences and gastroduodenal disease // Digestion. — 1987. — Vol. 37, suppl. 2. — P. 1-7.
9. Williams D.R. Analytical and computer simulation studies of a colloidal bismuth citrate system used as an ulcer treatment // J. Inorg. Nucl. Chem. — 1977. — Vol. 39, № 4. — P. 711-714.
10. Soutar R.L., Coghill S.B. Interaction of tripotassium dicitrato bismuthate with macrophages in the rat and in vitro // Gastroenterology. — 1986. — Vol. 91, № 1. — P. 84-93.
11. Coghill S.B., Hopwood D., McPherson S., Hislop S. The ultrastructural localisation of De-Nol (colloidal tripotassium dicitrato-bismuthate — TDB) in the upper
gastrointestinal tract of man and rodents following oral and instrumental administration // J. Pathol. — 1983. — Vol. 139, № 2. — P. 105-114.
12. Hollanders D., Morrissey S.M., Mehta J. Mucus secretion in gastric ulcer patients treated with tripotassium dicitrato bismuthate (De-Nol) // Br. J. Clin. Pract. —
1983. — Vol. 37, № 3. — P. 112-114.
13. Roberts N.B., Taylor W.H., Westcott C. Effect of cyclo-alkyl lactamimides upon amylase, lipase, trypsin and chymotrypsin // J. Pharm. Pharmacol. — 1982. —
Vol. 34, № 6. — P. 397-400.
14. Baron J.H., Barr J., Batten J. et al. Acid, pepsin, and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate
(De-Nol) // Gut. — 1986. — Vol. 27, № 5. — P. 486-490.
15. Wieriks J., Hespe W., Jaitly K.D. et al. Pharmacological properties of colloidal bismuth subcitrate (CBS, De-Nol) // Scand. J. Gastroenterol. — 1982. — Vol. 17,
suppl. 80. — P. 11-16.
Wiley & Sons Ltd., 2011. — 400 р.
2. Li W., Jin L., Zhu N. et al. Structure of colloidal bismuth subcitrate (CBS) in dilute HCl: unique assembly of bismuth citrate dinuclear units ([Bi(cit)2Bi]2-) // J. Am. Chem. Soc. — 2003. — Vol. 125, № 4. — P. 2408-12409.
3. Andrews P.C., Deacon G.B., Forsyth C.M. et al. Towards a structural understanding of the anti-ulcer and anti-gastritis drug bismuth subsalicylate // Angew Chem. Int. Ed. Engl. — 2006. — Vol. 45, № 34. — P. 5638-5642.
4. Mendis A.H.W., Marshall B.J. Helicobacter pylori and bismuth / Biological chemistry of arsenic, antimony and bismuth / H. Sun (Ed.). — Singapore: John Wiley & Sons Ltd., 2011. — 400 р.
5. Morgenstern A., Bruchertseifer F., Apostolidis C. Bismuth‑213 and Actinium‑225 — generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes // Current Radiopharmaceuticals. — 2012. — Vol. 5, № 3. — P. 221-227.
6. Lee S.P. A potential mechanism of action of colloidal bismuth subcitrate; diffusion barrier to hydrochloric acid // Scand. J. Gastroenterol. — 1982. — Vol. 17, suppl. 80. — P. 17-21.
7. Turner N.C., Martin G.P., Marriott C. The influence of native porcine gastric mucus gel on hydrogen ion diffusion: the effect of potentially ulcerogenic agents //
J. Pharm. Pharmacol. — 1985. — Vol. 37, № 11. — P. 776-780.
8. Tasman-Jones C., Maher C., Thomsen L. et al. Mucosal defences and gastroduodenal disease // Digestion. — 1987. — Vol. 37, suppl. 2. — P. 1-7.
9. Williams D.R. Analytical and computer simulation studies of a colloidal bismuth citrate system used as an ulcer treatment // J. Inorg. Nucl. Chem. — 1977. — Vol. 39, № 4. — P. 711-714.
10. Soutar R.L., Coghill S.B. Interaction of tripotassium dicitrato bismuthate with macrophages in the rat and in vitro // Gastroenterology. — 1986. — Vol. 91, № 1. — P. 84-93.
11. Coghill S.B., Hopwood D., McPherson S., Hislop S. The ultrastructural localisation of De-Nol (colloidal tripotassium dicitrato-bismuthate — TDB) in the upper
gastrointestinal tract of man and rodents following oral and instrumental administration // J. Pathol. — 1983. — Vol. 139, № 2. — P. 105-114.
12. Hollanders D., Morrissey S.M., Mehta J. Mucus secretion in gastric ulcer patients treated with tripotassium dicitrato bismuthate (De-Nol) // Br. J. Clin. Pract. —
1983. — Vol. 37, № 3. — P. 112-114.
13. Roberts N.B., Taylor W.H., Westcott C. Effect of cyclo-alkyl lactamimides upon amylase, lipase, trypsin and chymotrypsin // J. Pharm. Pharmacol. — 1982. —
Vol. 34, № 6. — P. 397-400.
14. Baron J.H., Barr J., Batten J. et al. Acid, pepsin, and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate
(De-Nol) // Gut. — 1986. — Vol. 27, № 5. — P. 486-490.
15. Wieriks J., Hespe W., Jaitly K.D. et al. Pharmacological properties of colloidal bismuth subcitrate (CBS, De-Nol) // Scand. J. Gastroenterol. — 1982. — Vol. 17,
suppl. 80. — P. 11-16.
Downloads
Download data is not yet available.